Company / Financials
Kymera Therapeutics, Inc. Financials
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$39.2M
FY2025 · -16.7% YoY
Net Income
-$311.4M
FY2025 · -39.1% YoY
Profit Margin
-794.0%
FY2025 · net income / revenue
ROE
-19.7%
FY2025 · return on equity
Total Assets
$1.7B
FY2025
Total Debt
-
FY2025
Equity
$1.6B
FY2025
ROA
-17.9%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$39.2M-16.7% YoYNet Income HistoryProfit after all expenses and taxes-$311.4M-39.1% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$39.2M-16.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$349.4M-33.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$68.2M+7.3% YoYR&D Expense HistoryResearch and development spending$316.6M+31.8% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$2.52+12.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.52+12.2% YoYShares Outstanding HistoryWeighted average diluted shares outstanding64.9M+16.7% YoY